FCYC+Conventional treatment + conventional treatment
ApprovedRecruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cognitive Impairment
Conditions
Cognitive Impairment, Intracerebral Hemorrhage
Trial Timeline
Nov 4, 2024 → Jun 30, 2026
NCT ID
NCT06673602About FCYC+Conventional treatment + conventional treatment
FCYC+Conventional treatment + conventional treatment is a approved stage product being developed by Brain Biotech for Cognitive Impairment. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06673602. Target conditions include Cognitive Impairment, Intracerebral Hemorrhage.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06673602 | Approved | Recruiting |
Competing Products
20 competing products in Cognitive Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aricept (donepezil hydrochloride) + placebo | Eisai | Approved | 85 |
| Donepezil | Eisai | Approved | 85 |
| Aricept | Eisai | Phase 2 | 52 |
| Donanemab + Aducanumab | Eli Lilly | Phase 3 | 77 |
| ABT-126 + Placebo | AbbVie | Phase 2 | 52 |
| SDI-118 + Placebo | AbbVie | Phase 1 | 33 |
| ABT-288 Low Dose + Placebo + ABT-288 High Dose | AbbVie | Phase 2 | 52 |
| AZD5213 + AZD5213 + AZD5213 | AstraZeneca | Phase 2 | 52 |
| MK-8931 | Merck | Phase 1 | 33 |
| Nicotine patch + MK-4334 + Placebo patch + Placebo capsule | Merck | Phase 1 | 33 |
| Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) | Merck | Phase 3 | 77 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Rivastigmine | Novartis | Approved | 85 |
| Exelon (rivastigmine) + Placebo | Novartis | Approved | 85 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Eviplera | Gilead Sciences | Approved | 84 |
| atorvastatin | Pfizer | Pre-clinical | 22 |
| bosutinib | Pfizer | Phase 1 | 32 |
| Aducanumab + Placebo | Biogen | Phase 2 | 49 |
| BIIB080 + BIIB080-matching placebo | Biogen | Phase 2 | 49 |